Filing summary
Entity and period: The supplied filing is Isoray, Inc.’s Form 10-Q for the quarter ended September 30, 2021 (the first quarter of fiscal 2022), not a filing identified as Perspective Therapeutics. The summary below reflects the filing text provided.
Business context
Isoray manufactures and sells Cesium-131 brachytherapy seeds (Cesium Blu) for cancer treatment. Revenue is primarily domestic; prostate brachytherapy represented 77% of quarterly sales. The statements are unaudited.
Financial results and liquidity
| Metric (USD millions, except percentages and per-share data) | Quarter ended Sep. 30, 2021 | Quarter ended Sep. 30, 2020 |
|---|---|---|
| Net sales | $2.564 | $2.384 |
| Cost of sales | $1.535 | $1.138 |
| Gross profit / gross margin | $1.029 / 40% | $1.246 / 52% |
| Operating expenses | $3.303 | $1.960 |
| Operating loss | $(2.274) | $(0.714) |
| Net loss | $(2.243) | $(0.713) |
| Basic and diluted loss per share | $(0.02) | $(0.01) |
| Cash used in operations | $(2.084) | $(0.338) |
| Capital expenditures | $0.054 | $0.113 |
- At September 30, 2021, cash and cash equivalents were $61.690 million, restricted cash was $0.182 million, and working capital was $63.159 million. The current ratio was 36.11.
- Total liabilities were $2.951 million, including $0.715 million of lease liabilities. The filing reports no financing activities in the quarter and no off-balance-sheet arrangements.
- Cash, cash equivalents, and restricted cash decreased by $2.138 million during the quarter. The larger operating cash use included a $0.796 million inventory cash outflow, principally associated with enriched barium carbonate purchases.
Material changes versus the prior-year quarter
- Sales rose 8%, but cost of sales increased 35%; gross profit fell 17% and gross margin declined from 52% to 40%.
- Research and development increased 125% to $0.702 million; sales and marketing rose 31% to $0.761 million; and general and administrative expenses rose 72% to $1.840 million. The filing attributes the increase in G&A in part to higher payroll, public-company, insurance, legal, audit, and share-based compensation costs.
- Share-based compensation was $0.596 million versus $0.085 million. The company granted approximately 2.95 million options during the quarter; common shares outstanding remained 141.9 million.
- Other sales, including non-prostate applications and services, increased 20%; prostate sales increased 4%. The filing says approximately 50% of revenue depended on three customers, with approximately 29% generated by one customer group.
Outlook, commentary, and risks
- Management said existing cash was expected to fund projected operating needs for the next 12 months. It targeted 25% revenue growth in fiscal 2022 but acknowledged missing that target in the first quarter and gave no assurance it would be achieved. Under assumptions including sustained growth and a GammaTile contribution, management estimated cash-flow break-even in three to four years.
- Management attributed weaker-than-forecast case volumes to COVID-19 and the Delta variant, delayed or canceled procedures, physician vacations, and hospital staffing constraints. It also cited unused isotope, higher material costs, and increased labor and depreciation as factors pressuring gross profit.
- Cesium-131 supply depends on Russian suppliers and reactor availability. A September 2021 consignment agreement involved $0.720 million of enriched barium carbonate; at quarter-end, the company estimated the remaining enriched barium could produce 5,894 curies. The filing cautions that there is no assurance the agreement or third-party reactor will remain available through full use of the material.
- Development activity includes studies of Cesium-131 in combination with immunotherapy, a provisional patent application for directional dosing, and evaluation of Sirius MRI markers. The filing describes timing and adoption as uncertain. Construction of a planned production facility remained on hold.
- CMS finalized a rule keeping brachytherapy and its sources on a fee-for-service model rather than including them in the Radiation Oncology Alternative Payment Model. Management viewed this as favorable but noted that future reimbursement proposals remain possible.
- The company stated that no material changes had occurred in its risk factors other than the disclosed customer concentration risk. It reported no legal proceedings and said disclosure controls were effective.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing names Isoray, Inc., whereas the request metadata names Perspective Therapeutics.
- Track sales growth, procedure volumes, and customer concentration, particularly the revenue dependence on three customers.
- Assess whether gross margins recover as isotope utilization, production costs, and sales volumes change.
- Monitor cash burn against management’s 12-month liquidity expectation and its conditional fiscal 2022 growth and break-even assumptions.
- Verify Cesium-131 supply continuity, reactor availability, and the timing and usability of consigned enriched barium inventory.
- Follow reimbursement policy, clinical adoption, and progress or timing of the disclosed studies, directional-dosing device, and MRI-marker evaluation.